@article{5b7cb8d3ff5c41a68412addb0963b94d,
title = "Intravenous versus subcutaneous immunoglobulin – Authors' reply",
author = "\{PATH study group\} and \{van Schaik\}, \{Ivo N.\} and Orell Mielke and Arman Sabet and Koshy George and Leslie Roberts and Ross Carne and Stefan Blum and Robert Henderson and \{Van Damme\}, Philip and Jelle Demeestere and Sandrine Larue and \{Pinard D'Amour\}, \{Catherine Andree\} and Vera Bril and Ari Breiner and Pavel Kunc and Martin Valis and Jana Sussova and Tomas Kalous and Radomir Talab and Michal Bednar and Toomas Toomsoo and Inna Rubanovits and Katrin Gross-Paju and Ulvi Sorro and Mika Saarela and Mari Auranen and Jean Pouget and Shahram Attarian and \{Le Masson\}, Gwendal and Wielanek-Bachelet, \{Anne C{\'e}cile\} and Claude Desnuelle and Emilien Delmont and Pierre Clavelou and Dominique Aufauvre and Jens Schmidt and Jana Zschuentssch and Claudia Sommer and Daniela Kramer and Olaf Hoffmann and Carsten Goerlitz and Judith Haas and Marko Chatzopoulos and Yoon, \{Min Suk\} and Ralf Gold and Peter Berlit and Andrea Jaspert-Grehl and David Liebetanz and Anna Kutschenko and Martin Stangel and Ericka Simpson",
note = "Funding Information: INvS chairs a steering committee for CSL Behring and received departmental honoraria for serving on scientific advisory boards for CSL Behring and Baxter. He received departmental research support from The Netherlands Organization for Scientific Research and from the Dutch Prinses Beatrix Fonds. All lecturing and consulting fees for INvS were donated to the Stichting Klinische Neurologie, a local foundation that supports research in the field of neurological disorders. INvS serves on the editorial board of the Cochrane Neuromuscular Disease Group, is a member of the organising committee of the Inflammatory Neuropathy Consortium, a standing committee of the Peripheral Nerve Society, and is a member of the Scientific Board of the Kreuth III meeting on the optimal use of plasma-derived medicinal products, especially coagulation factors and normal immunoglobulins organised under the auspices of the European Directorate for the Quality of Medicines and HealthCare. OM is a CSL employee and programme director for the PATH study. We thank Michael Tortorici for the insights in the pharmacokinetic modeling and simulations. ",
year = "2018",
month = may,
doi = "10.1016/S1474-4422(18)30109-1",
language = "English (US)",
volume = "17",
pages = "393--394",
journal = "The Lancet Neurology",
issn = "1474-4422",
publisher = "Lancet Publishing Group",
number = "5",
}